Compare AstraZeneca plc (AZN) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Humana Inc — how do they compare? AstraZeneca plc trades at $168.35 (market cap $253.13B), while Humana Inc trades at $409.05 (market cap $48.84B). The key difference: AstraZeneca plc is far larger — about 5.2× Humana Inc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | HUM | |
|---|---|---|
Market Cap | $253.13B | $48.84B |
Sector | Health | Health |
52-Week High | $209.48 | $409.42 |
52-Week Low | $137.44 | $163.67 |
Enterprise Value | $279.37B | $57.88B |
Dividend Yield | 1.92% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Humana (HUM) trades at $406.00, up 3.51% with strong technical bullish signals and recent earnings beats. The stock shows robust revenue growth reaching $129.66 billion in 2025, though net margins have compressed to 0.82%. Analyst sentiment is mixed with 32% buy ratings but a consensus price target of $354.33 below current levels. Recent developments include Medicare Advantage margin targets and Illinois Medicaid contract wins.
The outlook remains cautious despite operational strengths. While CenterWell expansion and margin recovery plans offer upside, current valuation at 43x P/E appears stretched relative to earnings growth. Key risks include regulatory scrutiny, healthcare utilization costs, and ongoing insider trading investigations that could pressure shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
